Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
Monte Rosa Therapeutics Inc
GLUE | US
16.52
USD-0.48
-2.82%
GLUE | US
Loading StockChartView...
About Monte Rosa Therapeutics Inc
Sector
Healthcare
Industry
Biotechnology
Earnings date
30/06/2024
As of date
10/06/2026
Close
16.52
Open
16.39
High
17.29
Low
16.28
Monte Rosa Therapeutics Inc. a clinical-stage biotechnology company engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. The company develops an orally bioavailable molecular glue degrader for GSPT1 a a translation termination factor for the treatment of Myc-driven cancers. It also develops CDK2 to treat ovarian uterine and breast cancers; NEK7 for the treatment of inflammatory diseases such as gout and Crohn's disease neurodegenerative disease diabetes and liver disease; VAV1 a target protein for autoimmune diseases; and a therapeutically-relevant protein in hemoglobinopathies. The company was incorporated in 2019 and is headquartered in Boston Massachusetts.
View LessGLUE | US
Risk
57.3
Sharpe
2.42
Luna's Score
51/100
Recommendation
Hold
Luna says (GLUE | US)
What's Working
Low Debt to Equity (< 0.25)
Low Debt to Asset (< 0.2)
Value Stock (Price to Book < 3)
Strong Sharpe Ratio (> 1.2)
What's not Working
Negative Momentum (Declining Price)
Price Below SMA10D
High Short-term Volatility
High 6-Month Volatility (>65%)
Smallcap (300M - 2B USD)
High Market Beta (> 0.8)
Weak Operating Margin (< 10%)
Volatility Signals
Bearish: Increased Volatility (6-month > 1-month volatility)
Risk Meter
Loading RiskMeterView...
10 days
62.1%1 month
57.3%3 months
52.5%6 months
88.9%Returns
Loading ReturnMeterView...
Fundamental Ratios
PE
-
Fwd. PE
-
Price to book
1.50
Debt to equity
0.20
Debt to assets
0.13
Ent. to EBITDA
-0.78
Ent. to rev.
20.68
PEG
-
Other Fundamentals
EBITDA
-131.78M
MarketCap
1.01B
MarketCap(USD)
1.01B
Div. yield
-
Op. margin
-695.25
Erngs. growth
-
Rev. growth
-
Ret. on equity
-59.51
Short ratio
11.58
Short perc.
13.04
Market Sentiment (SMA and Price signals)
Short-term: Bearish (SMA10D < SMA1M)
Intermediate-term: Bullish (SMA1M > SMA3M)
Long-term: Bullish (SMA6M > SMA12M)
SMAs: Stock Price Trends
Loading MovingAverageView...
Range10D
4.25
Range1M
5.16
Range3M
7.42
Volumes: Market Activity
Volume Averages
Loading VolumeAverageView...
Rel. volume
0.97
Price X volume
14.42M
Peers
Diversifiers
Industry Comparison
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | -0.78 | 0.53 | Cheaper |
| Ent. to Revenue | 20.68 | 3,967.00 | Cheaper |
| PE Ratio | - | 41.03 | - |
| Price to Book | 1.50 | 15.55 | Cheaper |
| Dividend Yield | - | 2.20 | - |
| Std. Deviation (3M) | 52.55 | 72.80 | Lower Risk |
| Debt to Equity | 0.20 | -1.23 | Expensive |
| Debt to Assets | 0.13 | 0.25 | Cheaper |
| Market Cap | 1.01B | 3.66B | Emerging |
